Drugs / Baminercept
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01164384 | Oct 2010 → Feb 2013 | chronic hepatitis C virus infection | University of Zurich | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01181089 | Sep 2010 → ? | secondary progressive multiple sclerosis | Biogen | Withdrawn | No outcome recorded |
| Phase 26 trials · 1 missed | ||||||
| Phase 2 | NCT01552681 | Jul 2012 → Jan 2015 | Sjogren syndrome | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | Missed primary |
| Phase 2 | NCT00664573 | Nov 2007 → Oct 2008 | rheumatoid arthritis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT00523328 | Aug 2007 → Oct 2008 | rheumatoid arthritis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT00664716 | Jul 2007 → Oct 2008 | rheumatoid arthritis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00458861 | Mar 2007 → Oct 2008 | rheumatoid arthritis | Biogen | Terminated | No outcome recorded |
| Phase 2 | NCT00292422 | Nov 2005 → May 2007 | rheumatoid arthritis | Biogen | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-10-09 | Biogen | Results Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis biogen.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2008-10-09 | Biogen | Biogen Idec Announces Top-Line Results from Phase II Clinical Trial of Baminercept in Rheumatoid Arthritis biogen.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Baminercept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01164384 ↗ |
| Known as | Baminercept alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00664573 ↗ |
| Known as | Baminercept alfa (rch) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742988 ↗ |
| Known as | BG9924 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00292422 ↗ |
| Known as | TT-47 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742988 ↗ |
| Action | Inhibit | “a lymphotoxin-beta receptor-immunoglobulin fusion protein that blocks the lymphotoxin-αβ/LIGHT axis” PMID 25405351 ↗ Nov 20141“Tumor necrosis factor ligand superfamily member 14 inhibitor” CHEMBL1742988 ↗ |
| Modality | Protein / enzyme biologic | “baminercept, a lymphotoxin-beta receptor-immunoglobulin fusion protein” PMID 25405351 ↗ Nov 2014 |
| Route | Subcutaneous | “multiple subcutaneous (SC) doses of BG9924” NCT00292422 ↗ |
| Target | TNFSF14 | “Tumor necrosis factor ligand superfamily member 14 inhibitor” CHEMBL1742988 ↗ |